FAQ

pidilizumab

Known as: Immunoglobulin G1, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal CT-011 Gamma1 Heavy Chain (220-213')-disulfide with Humanized Mouse Monoclonal CT-011 Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide, Glycosylated (CT-011 is Expressed in NSO Cells) 
A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1986-2016
024619862016

Related topics

Related topics

4 relations

Narrower (2)

CT-011MDV9300

Broader (1)

Monoclonal Antibodies
antigen binding

Related mentions per year

Related mentions per year

1948-2018
19401960198020002020
pidilizumab
Monoclonal Antibodies
antigen binding
CT-011
MDV9300

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Protective role of intratympanic nigella sativa oil against gentamicin induced hearing loss.
OBJECTIVE Aminoglycosides, used to combat with life-threatening infections, have a substantial risk of hearing loss. Nigella… (More)
Is this relevant?
2017
2017
Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma
Diffuse intrinsic pontine glioma (DIPG) is an incurable disease with a median overall survival of 10 months. Immune modulating… (More)
  • table 2
  • figure 1
  • figure 2
Is this relevant?
2016
2016
Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma
290. 10 Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen Y-B et al. Disabling immune tolerance by programmed death-1… (More)
  • figure 1
Is this relevant?
2015
2015
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
AIM We performed a meta-analysis of the risk of selected gastrointestinal toxicities associated with immune checkpoint inhibitors… (More)
  • figure 1
  • table 2
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
BACKGROUND Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2014
Review
2014
Pidilizumab in the treatment of diffuse large B-cell lymphoma.
INTRODUCTION The programmed death-1 (PD-1) immune checkpoint pathway is an emerging target in the treatment of hematologic… (More)
Is this relevant?
2014
2014
Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.
Immunotherapeutic strategies are promising approaches for the treatment of follicular lymphoma (FL). However, their efficacy may… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Second-line chemotherapy for patients with oesophagogastric adenocarcinoma.
8 www.thelancet.com/oncology Vol 15 January 2014 available and the future place of these drugs is diffi cult to comprehend but… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international…
PURPOSE The Programmed Death-1 (PD-1) immune checkpoint pathway may be usurped by tumors, including diffuse large B-cell lymphoma… (More)
Is this relevant?
2012
2012
Performance evaluation of small-animal multipinhole μSPECT scanners for mouse imaging
We compared the performance of three commercial small-animal μSPECT scanners equipped with multipinhole general purpose (GP) and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?